Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
54,097,996
-
Share change
-
-727,662
-
Total reported value
-
$1,601,222,557
-
Put/Call ratio
-
213%
-
Price per share
-
$29.64
-
Number of holders
-
159
-
Value change
-
-$17,874,204
-
Number of buys
-
79
-
Number of sells
-
56
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2021
As of 30 Jun 2021,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
159 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,097,996 shares.
The largest 10 holders included
BlackRock Inc., JPMORGAN CHASE & CO, VANGUARD GROUP INC, Palo Alto Investors LP, ALLIANCEBERNSTEIN L.P., Capital World Investors, ArrowMark Colorado Holdings LLC, WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, and JENNISON ASSOCIATES LLC.
This page lists
159
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.